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iron sucrose improves the attainment of target hemoglobin levels. In this randomized 
controlled	trial,	200	hemodialysis	patients	from	a	Dutch	teaching	hospital	were	in-






of high hemoglobin levels (>8.1	mmol/L)	was	lower	in	the	intervention	group	(median	
0.0%	vs	7.7%,	P =	.034).	The	weekly	dose	of	DA	was	lower	in	the	intervention	group	
(median	34.0	vs	46.9	mcg,	P =	 .020),	whereas	 iron	dose	was	higher	 (median	75	vs	
0	mg).	No	difference	was	found	for	the	percentage	of	hemoglobin	levels	below	the	
target	range.	In	conclusion,	a	pharmacist-managed	dosing	algorithm	for	DA	and	iron	
sucrose	 increased	 the	 attainment	 of	 target	 levels	 for	 hemoglobin	 and	 iron	 status,	
reduced	the	percentage	of	high	hemoglobin	levels,	and	was	associated	with	a	lower	
DA	and	a	higher	iron	sucrose	dose.
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particularly	 major	 adverse	 cardiovascular	 events	 (MACE).	 MACE	
comprise	 myocardial	 infarction,	 non-hemorrhagic	 stroke,	 and	 car-
diovascular	death,	the	latter	being	the	leading	cause	of	death	in	pa-
tients on hemodialysis.






approximately one out of eight hemodialysis patients treated with 
ESA	and	is	defined	as	the	failure	to	achieve	hemoglobin	target	levels	
with	higher	than	usual	ESA	doses.1,10,11
In	 2010,	 the	 European	 Renal	 Best	 Practice	 Work	 Group	 rec-
ommended	 that	 hemoglobin	 levels	 of	 6.8-7.4	mmol/L	 should	 gen-
erally	 be	 pursued,	 without	 intentionally	 exceeding	 the	 level	 of	
8.1	mmol/L.12	 In	clinical	practice,	 it	 is	challenging	to	meet	this	tar-
get	range.	Without	the	use	of	decision	aids,	only	about	30%	of	the	
hemodialysis	patients	in	Europe	have	within-target	hemoglobin	val-




bin	 levels	 are	 frequently	 overlooked.	 This	 leads	 to	 the	 erroneous	
continuation	of	(a	too	high	dose	of)	ESA,	which	occurs	in	more	than	
a quarter of hemodialysis patients in Europe.1
Iron	status	needs	to	be	sufficient	for	ESA	to	be	optimally	effective.	
Hemodialysis patients frequently have both an absolute and a func-
tional	iron	deficiency,	requiring	iron	supplementation.	Targets	for	iron	
therapy	 in	 hemodialysis	 patients	 are	 a	 transferrin	 saturation	 (TSAT)	
of	30%-50%	and	serum	ferritin	 levels	of	200-500	ng/mL.14 Data on 







ESA	 prescribing	 have	 shown	 promising	 results	 in	 patients	 with	
CKD,	eg	the	introduction	of	treatment	algorithms,16,17 and pharma-
cist-managed	 anemia	 programs.18-21	However,	 all	 published	 trials	
have	low	patient	numbers,	a	relatively	short	follow-up	and	often	an	
observational	design.	Therefore,	based	on	the	available	literature,	
no definite conclusions on the effectiveness of interventions to 
improve	ESA	prescribing	can	be	drawn,	and	high-quality	evidence	
is needed to confirm the promising results of earlier studies.
To	 fill	 this	 knowledge	 gap,	 we	 performed	 a	 randomized	 con-
trolled	 trial	 investigating	 whether	 a	 pharmacist-managed	 dosing	
algorithm for darbepoetin alfa and iron sucrose could improve the 
PTR per patient for hemoglobin and iron.








dialysis facility for 180 patients.
2.2 | Participants
Patients	were	eligible	 if	 they	were	undergoing	 intermittent,	mainte-
nance	hemodialysis,	and	were	treated	with	DA.	Written	informed	con-
sent was required before inclusion. The inclusion was open to both 
incident and prevalent hemodialysis patients. Exclusion criteria were 
allergic	reactions	to	DA	or	 iron	preparations,	and	failure	to	compre-
hend the inclusion procedure due to intellectual disabilities or poor 
Dutch language proficiency. Blood transfusions were permitted in 










Before	 the	start	of	 the	study,	 the	pharmacist	 investigators	 (FJvdO	
and	CFMHM)	developed	treatment	algorithms	for	the	dosing	of	DA	
and	iron	sucrose	in	the	intervention	group	(see	Figures	1	and	2).	The	
algorithms were based on the summary of product characteristics of 
DA	and	iron	sucrose	and	the	prevailing	anemia	treatment	guideline.12 
Principles incorporated in the treatment algorithms were discussed 
among pharmacist investigators and nephrologists and agreed upon 
in a consensus meeting:
•	 The	maximum	dose	of	DA	in	the	intervention	group	is	150	mcg/
week.
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•	 If	raising	the	DA	dose	to	150	mcg/week	does	not	increase	hemo-
globin,	DA	dose	will	be	reduced	to	the	previous	dose.
•	 A	period	of	at	 least	 three	weeks	 is	 required	between	 two	dose	
adjustments	for	DA.




• The dosing frequency of iron sucrose varies between once every 
2	weeks,	once	every	week,	and	thrice	weekly.
•	 In	case	of	a	decrease	 in	hemoglobin	of	1.0-2.0	mmol/L,	 the	ne-
phrologist will be contacted to inform if there has been a bleeding 
or	infection.	If	this	is	the	case,	the	DA	dose	will	not	be	increased.	
If	there	hasn't	been	any	bleeding	or	infection,	the	DA	dose	will	be	





• Blood transfusions are not incorporated in the algorithm and do 
not influence dose advice.
• Trends in hemoglobin are used to generate dose advice.
•	 Cut-off	values	for	dose	adjustments	are	slightly	higher	and	lower	
than the target range for hemoglobin to prevent cycling.
•	 The	dose	of	DA	and	iron	sucrose	will	not	be	changed	during	hos-
pitalization,	unless	on	the	nephrologist's	explicit	request.
•	 Only	 the	 pre-planned,	 monthly	 laboratory	 measurements	 are	
used	 to	 generate	 dose	 advice,	 for	 example	 hemoglobin	 levels	











had access to the developed treatment algorithms.
2.5 | Procedures
Monthly	laboratory	analyses	were	performed	for	hemoglobin	lev-




to the treating nephrologist for one of the four dialysis groups. 
Transfusion strategy was restrictive; transfusions were considered 
in	 the	 presence	 of	 stringent	 indications,	 for	 example,	 in	 case	 of	
(a)	very	low	hemoglobin	levels	(below	4.3	mmol/L),	(b)	hemoglobin	
levels	 below	 5.0	 mmol/L	 and	 symptoms,	 (c)	 pre-existing	 cardio-
vascular	disease,	(d)	previous	surgery	or	ESA	hyporesponsiveness.	
Dose recommendations were communicated by email. If the neph-
rologist	did	not	agree	with	 the	 recommendations,	discussion	 fol-
lowed. Cases in which the suggested dose was not accepted were 
registered	including	the	reason	for	the	deviation.	After	consensus	
regarding	the	doses	was	reached,	the	nephrologist	prescribed	the	
agreed	doses	 of	DA	 and	 iron	 sucrose.	Both	 drugs	were	 adminis-
tered at the end of the dialysis sessions. Dose changes were car-
ried	 out	 within	 one	 week	 after	 approval	 of	 dose	 advice	 by	 the	
nephrologist.
2.6 | Outcomes
The primary outcome measure was the median percentage of 
monthly	hemoglobin	values	in	the	follow-up	period	that	were	in	the	
target	range	(PTR,	hemoglobin	6.8-7.4	mmol/L).
Secondary	 outcome	 measures	 were	 as	 follows:	 (a)	 the	 per-
centage	 of	 hemoglobin	 levels	 in	 supratherapeutic	 range	 (PSTR,	
hemoglobin >8.1	 mmol/L)	 as	 a	 surrogate	 marker	 for	 suboptimal	
prescribing;	 (b)	 the	PTR	 for	 iron	 (defined	as	 a	 transferrin	 satura-
tion	of	at	 least	20%	and	 ferritin	200-500	mg/L),	and	 (c)	percent-
age	 of	 hemoglobin	 levels	 below	 target	 range	 (PBTR,	 hemoglobin	
<6.8	mmol/L).




least	 one	 transfusion	 during	 follow-up,	 and	 the	 robustness	 of	 the	
PBD method. Robustness was defined as the interindividual vari-
ation of the primary outcome measure amongst pharmacists and 
nephrologists. The algorithm was considered robust if the inter phar-
macist variation was less than the inter nephrologist variation.
F I G U R E  1  Treatment	algorithm	for	DA	dosage
F I G U R E  2   Treatment algorithm for intravenous iron sucrose
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2.7 | Sample size calculation
The sample size calculation was based on the assumption that PTR 
per	patient	for	hemoglobin	would	be	23%	in	the	control	group,	based	
on	historical	data	from	our	hospital	(data	not	shown).	We	estimated	
that the intervention could approximately double this percentage to 
45%.	We	calculated	 that	at	 least	150	patients	needed	 to	be	 rand-
omized (α	of	0.05	[two-sided],	β	of	0.20,	randomization	ratio	1:1)	to	
be able to reject the null hypothesis that the intervention and usual 





Participating patients were randomized to the intervention or the 
control	group,	 irrespective	of	dialysis	group,	and	 treating	neph-
rologist.	Randomization	was	performed	by	a	computer-generated	
sequencing	 (computer-generated	 1:1	 variable	 block	 randomiza-
tion).	The	random	allocation	sequence	was	provided	by	an	inde-
pendent party not involved in the conduct of the study or patient 
care. Three pharmacists enrolled participants. One pharmacist 
was responsible for treatment assignment by opaque sealed 
envelopes.
2.9 | Statistical methods
Data	 from	 all	 patients	 with	 at	 least	 3	 months	 of	 follow-up	 were	
included for assessment of all endpoints. This period was chosen 
because	 it	 takes	 approximately	 four	 weeks	 for	 ESA	 to	 increase	
hemoglobin values. This means that the effect of the interven-
tion	could	not	be	properly	assessed	 if	 follow-up	was	shorter	 than	
3 months.
The	nonparametric	Mann-Whitney	U	 test	was	used	 to	 test	 for	
differences	in	continuous	variables	with	skewed	distributions,	which	
was the case for all primary and predefined secondary outcome 




Statistics)	 and	OpenEpi	 (Open	 Source	 Epidemiologic	 Statistics	 for	
Public	 Health,	 Version	 3.01.	 www.OpenE	pi.com)	 for	 the	 IDR	 for	
mortality.	A	P-level	<.05	 (two-sided)	was	 considered	 to	 indicate	 a	
statistically significant difference.
2.10 | Ethical considerations
The procedures followed were in accordance with the Declaration 
of	 Helsinki.	 The	 Medical	 Research	 Ethics	 Review	 Board	 TWOR,	








Table 1 shows the baseline characteristics of the study popula-
tion.	In	the	control	group,	a	higher	prevalence	was	found	of	previous	







were subject to discussion between pharmacists and nephrologists 
of which 13 were finally rejected. Protocol adherence was therefore 
98.6	 percent.	 The	 primary	 reason	 for	 rejection	 was	 the	 patient's	
clinical situation: the nephrologist sometimes chose a higher dose 
of	DA	than	advised.	The	main	discussion	point	for	iron	supplementa-
tion was the dosing frequency: the pharmacist recommended thrice 
a	week	100	mg	in	some	cases,	whereas	the	nephrologist	preferred	
dosing	twice	a	week.	Analysis	was	performed	according	to	the	inten-
tion to treat principle.
F I G U R E  3   Patient flowchart
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3.1 | Outcomes




parameter that did not differ between both groups was the percent-




group and the variability in dose was high in both groups as shown 
by	the	large	interquartile	range	(Table	3).	The	iron	sucrose	dose	was	
higher in the intervention than in the control group with a median 
of	75	mg	 (IQR	50-100	mg)	 in	 the	 intervention	group	vs	0	mg	 (IQR	
0-100	mg)	in	the	control	group.	The	IDR	for	mortality	was	0.59	for	
the	intervention	vs	the	control	group	(95%	CI	0.31-1.10).




The percentage of patients in the intervention group with at 
least	one	transfusion	during	follow-up	was	lower	than	in	the	control	
group	(20.2%	vs	34.1%,	P =	.046).	The	number	of	transfused	units	of	




gorithm	of	DA	and	 iron	 sucrose	 is	 effective	 in	 improving	 the	PTR	
per	patient	 for	 hemoglobin,	 reducing	ESA	dose	 and	 reducing	 sub-
optimal prescribing. These results may be explained by restricting 
dose	 increases	 of	 DA	 during	 infections	 and	 bleeding,	 more	 focus	
on	 preventing	 supratherapeutic	 hemoglobin	 levels,	 and	more	 pro-
active	iron	supplementation	in	the	intervention	group,	which	led	to	




TA B L E  1   Baseline characteristics
Intervention 


























Diabetes mellitus 37	(39.4) 42	(46.1)
Heart failure 18	(19.1) 17	(18.7)
Ischemic heart disease 26	(27.7) 35	(38.5)


















PSTR	per	patient	for	hemoglobin) 0.0	(0.0-12.9) 7.7	(0.0-27.3) .034
PBTR per patient for hemoglobin 30.8	(15.4-40.0) 30.8	(9.1-50.0) .864




TA B L E  2   Primary and secondary 
outcomes
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The higher PTR per patient for hemoglobin in the intervention 
group,	 is	 in	 line	 with	 the	 results	 from	 earlier	 studies	 regarding	
algorithm-based	 dosing	 and	 pharmacist-managed	 renal	 anemia	
programs. In these studies in patients with different stages of 
CKD,	pharmacist	and	algorithm-based	interventions	led	to	higher	
percentages of hemoglobin levels within the target range.16-19,23 
However,	a	comparison	with	our	results	is	difficult,	as	the	applied	
target ranges for hemoglobin in earlier studies were broader than 
recommended	 in	 the	 prevailing	 guidelines,	 and	 patients	 in	 our	
study	were	older	 and	had	more	 comorbidities.	Most	 of	 the	 pre-
vious studies included only a small percentage of all assessed pa-
tients. This raises questions about the external validity of these 
earlier data. The best comparison can probably be made with 
real-life	 data	 from	 the	 EURODOPPS	 database.	 In	 this	 database,	
which comprises registry data of hemodialysis patients from seven 
European	countries,	31.2%	of	hemodialysis	patients	had	hemoglo-
bin	levels	within	target	range	in	the	period	of	2009	to	2011,	with	




rithm exceeds the standard level of care in Europe.
Apart	 from	 increasing	the	percentage	of	within-target	hemo-
globin	 levels,	 our	 algorithm-based	 dosing	 regimen	 also	 led	 to	 a	
lower	weekly	dose	of	DA	with	a	median	of	34.0	mcg	in	the	inter-
vention	vs	46.9	mcg	in	the	control	group.	This	reduction	was	com-
parable	 to	 the	 results	 of	 earlier	 studies	 of	 pharmacist-managed	
renal	anemia	programs	and	algorithm-based	dosing,	with	reported	
dose	reductions	of	10%-62%.19,21,23-25	The	reduction	in	ESA	dose	
in our study was not counterbalanced by an increase in transfu-
sions,	as	transfusions	were	less	frequent	in	the	intervention	group.
Due	 to	proactive	prescribing	 in	 the	pharmacist-managed	 treat-
ment	group,	the	dose	of	intravenous	iron	sucrose	and	the	percentage	
of iron status within the target range were higher in the intervention 
than	 in	the	control	group	(median	75	vs	0	mg,	and	21.1%	vs	8.3%,	
respectively).	The	median	weekly	iron	sucrose	dose	of	0	mg	in	the	
control	group	 indicates	 that	 for	at	 least	50%	of	 the	 time,	patients	








data	 from	our	 study	and	EURODOPPS	show	 that	 suboptimal	pre-
scribing is a common and relevant problem in hemodialysis patients.
One of the strengths of our study is the small number of exclu-
sion	criteria.	As	a	 result,	our	study	population	 is	 representative	of	






outcome	 was	 calculated	 to	 be	 99.3%.	 Also,	 the	 loss	 to	 follow-up	
during	the	trial	was	very	limited	(15	patients).
Notwithstanding	 these	 strengths,	 several	 limitations	 need	 to	
be	mentioned.	First,	despite	randomization,	differences	in	baseline	
characteristics were observed between both groups. In the control 
group,	 patients	 were	more	 often	male,	 the	mean	 age	was	 almost	
5	years	higher,	and	diabetes,	ischemic	heart	disease,	and	peripheral	
vascular	 disease	 were	 more	 prevalent.	 In	 the	 intervention	 group,	
more	patients	 suffered	 from	atrial	 fibrillation	and	 stroke/TIA.	The	
influence of these comorbidities on the percentage of hemoglobin 
within-target	levels	has	not	been	described	in	literature,	but	may	ex-
plain	why	mortality	in	the	study	population,	especially	in	the	control	
group,	was	higher	 than	reported	elsewhere.26,27 We could not de-
termine	a	cause	for	the	age	difference	between	treatment	groups,	
as the randomization procedure was adequate and strictly followed. 
No	differences	in	reasons	for	drop	out	were	seen	between	patients	




























     |  7 of 8VAN DEN OEVER Et Al.
of	dose	changes	were	very	rare,	we	do	not	expect	this	to	have	influ-
enced our results.















evant source of bias.
Although	the	good	internal	validity	of	this	trial	supports	a	firm	
conclusion	in	the	study	population,	its	external	validity	and	appli-
cability	 to	other	countries,	 such	as	 the	United	States	and	Japan,	
need further investigation to verify the influence of healthcare 
structure	 and	 patient	 characteristics,	 such	 as	 ferritin	 levels,	 di-
alysis	vintage,	 and	 intrapatient	hemoglobin	variability,	which	are	
known	to	be	highly	variable	between	regions	worldwide.17,18,25,28 
Although	 recent	changes	 in	hemoglobin	 target	 range	hamper	di-
rect extrapolation and use of existing algorithms in current prac-
tice,	this	trial	shows	that	our	intervention	is	effective	in	improving	
the percentage per patient in the target range for hemoglobin. 
As	 the	 algorithms	 can	 easily	 be	 adapted	 to	 comply	with	 current	
guidelines,	there	is	no	major	barrier	to	the	implementation	of	our	
intervention.	An	individualized	hemoglobin	target	range,	based	on	
guidelines,	 patient	 characteristics,	 and	 shared	 decision	 making,	






tervention may be equally effective when carried out by another in-
dependent,	trained	healthcare	professional.
Future research should focus on the effectiveness of our inter-
vention when using an individualized target range. Cardiovascular 
morbidity	and	mortality,	and	all-cause	mortality	should	be	assessed	
as	outcomes.	To	 fully	 utilize	 the	potential	 of	 our	 intervention,	 the	
procedure of implementing proposed dose changes should be as 
simple as possible and incorporation of the algorithms in a clinical 
decision	support	system	or	web-/digital	application	is	recommended.
Our	trial	confirms	the	superiority	of	pharmacist-managed	dosing	
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